Risperidone (4 mg tablets): Supply issue

Supply issue Active

There is a supply issue affecting Risperidone (Teva) tablets 4 mg presentation.

16 April 2025

There continues to be a supply constraint affecting the 4 mg presentation of Risperidone Teva. Stock of the alternative, Risperdal, has run out. 

Two x 2 mg risperidone tablets can be taken where the 4 mg tablet is not available.

Affected product

There is a supply issue affecting:

Chemical Brand Presentation Pharmacode Subsidy Measure/Qty
Risperidone Risperidone (Teva) Tab 4 mg 2466937 $6.25 per 60

Schedule listing: Risperidone(external link)

Alternative: two x 2 mg tablets

Unfortunately, stock of the 4 mg Risperdal alternative has run out. We are advised that two x 2 mg risperidone tablets can be used as an alternative.

Chemical Brand Presentation Pharmacode Subsidy Measure/Qty
Risperidone Risperdal Tab 4 mg 245402 $6.25 per 60

Medsafe datasheet for Risperdal(external link)

The oral liquid is also available in significant quantities. However, people would need a new prescription.

We listed other brands and strengths to support earlier supply issues affecting risperidone.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)